He et al. developed a CRGs scoring system that accurately predicts prognosis, as well as initially identified glycine cleavage system protein H (GCSH), a cuproptosis key gene, as a reliable therapeutic target or prognostic indicator for CCA patients [162]. This evidence concerns the gene GCSH and cholangiocarcinoma.